

ITW

JENKINS  
WILSON  
& TAYLOR

attorneys  
October 13, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 13, 2005.

Christi A. Butner  
Christi A. Butner  
Date of Signature: 10-13-2005

RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

E. ERIC MILLS

BENTLEY J. OLIVE

\*CHRIS PERKINS, PH.D.

\*\*JAMES DALY IV, PH.D.

JEFFREY CHILDERS, PH.D.

P. ASHLEY DARDEN

CHRISTOPHER B. LEE

TECHNICAL SPECIALIST  
AMY ODENBAUGH, PH.D.

\*LICENSED ONLY IN CA

\*\*LICENSED ONLY IN KY

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/796,657 for  
COMPOUNDS, METHODS AND COMPOSITIONS USEFUL  
FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA  
VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV)  
INFECTION

Our Ref. No. 421/60/18/2/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (2 pages) in duplicate;
3. Copies of cited references (14 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.  
Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/cab  
Enclosures  
Customer No: 25297



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 13, 2005.

Christi A. Butner

Christi A. Butner  
Date of Signature

10-13-2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dykstra et al.

Group Art Unit: 1626

**Serial No.: 10/796,657**

Examiner: Grazier, Nyeemah

Filed: March 9, 2004

Docket No.: 421/60/18/2/2 DIV

For: COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE  
TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND  
HEPATITIS C VIRUS (HCV) INFECTION

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.


Serial No.: 10/796,657

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.


Date: 10/13/2005

By:   
Arles A. Taylor, Jr.  
Registration No. 39,395

AAT/acy

Enclosures

Customer No: 25297



FORM PTO-1449 U.S. Department of Commerce  
Patent and Trademark Office

List of Documents Cited by Applicant

Application No.:	10/796,657
Filing Date:	March 9, 2004
First Named Inventor:	Dykstra et al.
Group:	1624
Examiner:	Nyeemah Grazier
Attorney Docket No.:	421/60/18/2/2

### U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	1	FR 1,464,999	12/31/1965	Harnisch et al.		
	2	GB 1,084,175	9/20/1967	CIBA Limited		
	3	BE 641,607	6/22/1964	CIBA Societe Anonyme		
	4	WO 01/03685 A2	1/18/2001	Boykin et al.		
	5	WO 01/46175 A1	6/28/2001	Wilson et al.		

### OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	6	European Search Report for corresponding European app. no. 02705743.9 dated July 15, 2005.	
	7	BOYKIN ET AL., "Anti-Pneumocystis Activity of Bis-Amidoximes and Bis-O-Alkylamidoximes Prodrugs", <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , <b>6 (24)</b> : 3017-3020, 1996.	
	8	WANG ET AL., "Specific Molecular Recognition of Mixed Nucleic Acid Sequences: An Aromatic Dication that Binds in the DNA minor Groove as a Dimer", <u>PNAS</u> , <b>97 (1)</b> : 12-16, January 4, 2000.	
	9	TRALIC-KULENOVIC ET AL., "Synthesis and Absorption Spectral Properties of Substituted Phenylfurylbenzothiazoles and their Vinylogues", <u>Monatshefte fur Chemie</u> , <b>125</b> : 209-215, 1994.	

	10	GELUS ET AL., "Inhibition of HIV-1 Tat-TAR Interaction by Diphenylfuran Derivatives: Effects of the Terminal Basic Side Chains", <u>Bioorganic &amp; Medicinal Chemistry</u> , <b>7</b> : 1089-1096, 1999.	
	11	ZAPP ET AL., "Modulation of the Rev-RRE Interaction by Aromatic Heterocyclic Compounds", <u>Bioorganic &amp; Medicinal Chemistry</u> , <b>5 (6)</b> : 1149-1155, 1997.	
	12	RATMEYER ET AL., "Inhibition of HIV-1 Rev-RRE Interaction by Diphenylfuran Derivatives", <u>Biochemistry</u> , <b>35</b> : 13689-13696, 1996.	
	13	DE CLEREQ ET AL., "Diaryl Amidine Derivatives as Oncornaviral DNA Polymerase Inhibitors", <u>J. Med. Chem.</u> , <b>23</b> : 787-795, 1980	
	14	WANG ET AL., "Evaluation of the Infulence of Compound Structure on Stacked-Dimer Formation in the DNA Minor Groove", <u>Biochemistry</u> , <b>40</b> : 2511-2521, 2001.	

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.